BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol 2021;12:636568. [PMID: 33767702 DOI: 10.3389/fimmu.2021.636568] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Demuynck R, Efimova I, Naessens F, Krysko DV. Immunogenic ferroptosis and where to find it? J Immunother Cancer 2021;9:e003430. [PMID: 34903554 DOI: 10.1136/jitc-2021-003430] [Reference Citation Analysis]
2 García-Sancha N, Corchado-Cobos R, Bellido-Hernández L, Román-Curto C, Cardeñoso-Álvarez E, Pérez-Losada J, Orfao A, Cañueto J. Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5134. [PMID: 34680282 DOI: 10.3390/cancers13205134] [Reference Citation Analysis]
3 Ye Z, Shi Y, Lees-Miller SP, Tainer JA. Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy. Front Immunol 2021;12:797880. [PMID: 34970273 DOI: 10.3389/fimmu.2021.797880] [Reference Citation Analysis]
4 Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, Ni C, Chen Z. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res 2021;9:59. [PMID: 34294146 DOI: 10.1186/s40364-021-00312-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Reference Citation Analysis]
6 Cilibrasi C, Papanastasopoulos P, Samuels M, Giamas G. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. Int J Mol Sci 2021;22:12015. [PMID: 34769447 DOI: 10.3390/ijms222112015] [Reference Citation Analysis]
7 Huang YK, Busuttil RA, Boussioutas A. The Role of Innate Immune Cells in Tumor Invasion and Metastasis. Cancers (Basel) 2021;13:5885. [PMID: 34884995 DOI: 10.3390/cancers13235885] [Reference Citation Analysis]
8 Shklovskaya E, Rizos H. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. Int J Mol Sci 2021;22:6741. [PMID: 34201655 DOI: 10.3390/ijms22136741] [Reference Citation Analysis]
9 Ollivier L, Labbé M, Fradin D, Potiron V, Supiot S. Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer. Front Oncol 2021;11:744679. [PMID: 34595122 DOI: 10.3389/fonc.2021.744679] [Reference Citation Analysis]
10 Turchan WT, Pitroda SP, Weichselbaum RR. Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci 2021;22:9573. [PMID: 34502479 DOI: 10.3390/ijms22179573] [Reference Citation Analysis]
11 Krenz B, Gebhardt-Wolf A, Ade CP, Gaballa A, Roehrig F, Vendelova E, Baluapuri A, Eilers U, Gallant P, D'Artista L, Wiegering A, Gasteiger G, Rosenfeldt MT, Bauer S, Zender L, Wolf E, Eilers M. MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. Cancer Res 2021;81:4242-56. [PMID: 34145038 DOI: 10.1158/0008-5472.CAN-21-1677] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Batool S, Bin-T-Abid D, Batool H, Shahid S, Saleem M, Khan AU, Hamid A, Mahmood MS, Ashraf NM. Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing. Expert Opin Biol Ther 2021;21:1525-33. [PMID: 34547976 DOI: 10.1080/14712598.2021.1981285] [Reference Citation Analysis]
13 Retecki K, Seweryn M, Graczyk-Jarzynka A, Bajor M. The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. Cancers (Basel) 2021;13:6012. [PMID: 34885122 DOI: 10.3390/cancers13236012] [Reference Citation Analysis]
14 Elkoshi Z. Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites? Front Immunol 2022;13:821598. [DOI: 10.3389/fimmu.2022.821598] [Reference Citation Analysis]
15 Zhou W, Xu S, Deng T, Zhou R, Wang C. LncRNA USP30-AS1 promotes the survival of acute myeloid leukemia cells by cis-regulating USP30 and ANKRD13A. Hum Cell 2021. [PMID: 34694569 DOI: 10.1007/s13577-021-00636-7] [Reference Citation Analysis]
16 Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021;27:1345-56. [PMID: 34385702 DOI: 10.1038/s41591-021-01450-2] [Reference Citation Analysis]
17 Nguyen TB, Lane DP, Verma CS. Can Glycosylation Mask the Detection of MHC Expressing p53 Peptides by T Cell Receptors? Biomolecules 2021;11:1056. [PMID: 34356680 DOI: 10.3390/biom11071056] [Reference Citation Analysis]
18 Lv L, Wei Q, Wang Z, Zhao Y, Chen N, Yi Q. Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma. Front Bioeng Biotechnol 2021;9:690186. [PMID: 34307322 DOI: 10.3389/fbioe.2021.690186] [Reference Citation Analysis]
19 Cuyler J, Murthy P, Spada NG, McGuire TF, Lotze MT, Xie XQ. Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy. Drug Discov Today 2021:S1359-6446(21)00405-0. [PMID: 34592447 DOI: 10.1016/j.drudis.2021.09.011] [Reference Citation Analysis]
20 Yang E, Chua W, Ng W, Roberts TL. Peripheral Cytokine Levels as a Prognostic Indicator in Gastric Cancer: A Review of Existing Literature. Biomedicines 2021;9:1916. [PMID: 34944729 DOI: 10.3390/biomedicines9121916] [Reference Citation Analysis]
21 Murtadha AH, Azahar IIM, Sharudin NA, Has ATC, Mokhtar NF. Influence of nNav1.5 on MHC class I expression in breast cancer. J Biosci 2021;46. [DOI: 10.1007/s12038-021-00196-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Eptaminitaki GC, Wolff N, Stellas D, Sifakis K, Baritaki S. Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy. Cells 2021;10:3313. [PMID: 34943820 DOI: 10.3390/cells10123313] [Reference Citation Analysis]
23 Dymova MA, Kuligina EV, Richter VA. Molecular Mechanisms of Drug Resistance in Glioblastoma. Int J Mol Sci 2021;22:6385. [PMID: 34203727 DOI: 10.3390/ijms22126385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Watanabe K, Nishikawa H. Engineering strategies for broad application of TCR-T and CAR-T cell therapies. Int Immunol 2021:dxab052. [PMID: 34374779 DOI: 10.1093/intimm/dxab052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J, Deutsch AJ. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. Int J Mol Sci 2021;22:13311. [PMID: 34948104 DOI: 10.3390/ijms222413311] [Reference Citation Analysis]
26 Noonepalle SKR, Karabon L, Chiappinelli KB, Villagra A. Editorial: Genetic and Epigenetic Control of Immune Responses. Front Immunol 2021;12:775101. [PMID: 34675944 DOI: 10.3389/fimmu.2021.775101] [Reference Citation Analysis]